Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ligand Pharm (NQ: LGND )

99.93 +1.15 (+1.16%)
Streaming Delayed Price Updated: 3:32 PM EDT, Sep 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ligand Pharm

< Previous 1 2 3 4 5 6 Next >
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Looking Into Ligand Pharmaceuticals's Recent Short Interest
Via Benzinga
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
After Monday's panicked global sell-off, markets have calmed down. 
Via Investor's Business Daily
Assessing Ligand Pharmaceuticals: Insights From 6 Financial Analysts
Via Benzinga
What 4 Analyst Ratings Have To Say About Ligand Pharmaceuticals
Via Benzinga
LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
LGND stock results show that Ligand Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Halozyme And Ligand — Two Leading Biotechs — Smash Quarterly Forecasts
Halozyme and Ligand beat second-quarter expectations late Tuesday. But only one of the biotech stocks jumped. 
Via Investor's Business Daily
Ligand Reports Second Quarter 2024 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024
From Ligand Pharmaceuticals Incorporated
Via Business Wire
5 Best Short-Term Stocks to Consider Investing In
Looking for the best short-term stocks? Explore our top picks and learn how to navigate the risks and opportunities in fast-paced stock trading. 
Via MarketBeat
Ligand to Acquire APEIRON Biologics AG for $100 Million
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Lifecore Biomedical Announces Cooperation Agreement with 22NW
Provides for the Addition of 22NW Nominees Jason Aryeh and Matthew Korenberg, as Well as Humberto Antunes and Paul Johnson, to the Board 
From Lifecore Biomedical, Inc.
Via GlobeNewswire
Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand to Participate in Upcoming Investor Conferences
From Ligand Pharmaceuticals Incorporated
Via Business Wire
3 Magnificent Growth Stocks to Buy Hand Over Fist
Small-cap stocks could get a boost from the central bank's anticipated rate cuts in 2025. These three stocks may be a great way to get ahead of this catalyst. 
Via The Motley Fool
Topics Economy
Exposures Interest Rates
3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off
With the innovation space possibly getting overstretched, these biotech stocks to buy could benefit from a sector rotation. 
Via InvestorPlace
LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
LGND stock results show that Ligand Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Ligand Reports First Quarter 2024 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Don't Overlook These Top Medical Stocks As Q1 Earnings Approach
While the tech sector has led the Q1 earnings season, investors shouldn’t overlook these top medical stocks. To that point, the growth and expansion of Ligand Pharmaceuticals, Oscar Health, and... 
Via Talk Markets
Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
From Ligand Pharmaceuticals Incorporated
Via Business Wire
7 Small-Cap Stocks for the Thinking Speculator
While these small-cap stocks may be miles away from Wall Street’s spotlight, they’re compelling enough to deliver some big surprises. 
Via InvestorPlace
Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Why Is Ligand Pharmaceuticals Stock Trading Higher Today?
Ligand Pharmaceuticals beats Q4 2023 sales estimates at $28.1 million, with strong core Captisol and royalty figures. CEO Todd Davis highlights transformative 2023 and optimistic guidance for 2024. 
Via Benzinga
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.